TCG extends master service agreement with Pfizer

Research firm TCG Lifesciences (TCGL) today said it has extended its master service agreement with the global pharma giant Pfizer.

"We are excited at the prospect of supporting Pfizer across the drug discovery and development value chain in an integrated manner," TCG Lifesciences Managing Director Swapan Bhattacharya said in a statement.

This development is of great importance for us, as it signifies our competence in providing innovation-based integrated research services from early stage of discovery of potential drugs to the large scale production, he added.

TCGL has been a preferred research provider to Pfizer primarily in the field of discovery of new chemical entities, which can be developed into potential drug.

From now, the research firm would also provide integrated research services, through its 'one box' model covering areas such as medicinal chemistry and biological screening to enhance Pfizer's drug discovery pipeline.